We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
InflaRx N.V. (NASDAQ:IFRX) on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback